S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
The Most Bought AI Stock by Congress Isn’t NVIDIA
5 Dividend Kings Stocks to Load Up on Now
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
The Most Bought AI Stock by Congress Isn’t NVIDIA
5 Dividend Kings Stocks to Load Up on Now
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
The Most Bought AI Stock by Congress Isn’t NVIDIA
5 Dividend Kings Stocks to Load Up on Now
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
The Most Bought AI Stock by Congress Isn’t NVIDIA
5 Dividend Kings Stocks to Load Up on Now
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
NASDAQ:BIOL

BIOLASE (BIOL) Stock Price, News & Analysis

$0.19
+0.03 (+18.62%)
(As of 03/27/2024 ET)
Today's Range
$0.15
$0.20
50-Day Range
$0.13
$1.03
52-Week Range
$0.13
$47.10
Volume
10.01 million shs
Average Volume
11.26 million shs
Market Capitalization
$6.21 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$77.00

BIOLASE MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
40,193.0% Upside
$77.00 Price Target
Short Interest
Healthy
0.94% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.25mentions of BIOLASE in the last 14 days
Based on 13 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
N/A

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.29 out of 5 stars

BIOL stock logo

About BIOLASE Stock (NASDAQ:BIOL)

BIOLASE, Inc., together with its subsidiaries, develops, manufactures, markets, and sells laser systems for dental practitioners and their patients in the United States and internationally. Its dental laser systems allow dentists, periodontists, endodontists, pediatric dentists, oral surgeons, and other dental specialists to perform a range of minimally invasive dental procedures, including cosmetic, restorative, and complex surgical applications. The company offers Waterlase all-tissue dental laser systems for cutting soft and hard tissues; diode soft-tissue laser systems for soft tissue, hygiene, temporary pain relief, teeth whitening, and cosmetic procedures; and Epic Hygiene laser to manage non-surgical periodontitis and enhance clinical production. It also manufactures and sells consumable products and accessories for its laser systems, as well as markets flexible fibers and hand pieces; and sells teeth whitening gel kits. The company sells its products through its field sales force and distributor network. The company was formerly known as BIOLASE Technology, Inc. and changed its name to BIOLASE, Inc. in 2012. BIOLASE, Inc. was founded in 1984 and is headquartered in Foothill Ranch, California.

BIOL Stock Price History

BIOL Stock News Headlines

BIOLASE (NASDAQ:BIOL) Now Covered by StockNews.com
[BUY ALERT] Our #1 A.I. Stock for March
It's the one AI stock nobody is talking about. Cathy Wood just bought 11 million shares of it.
Why BIOLASE Shares Are Surging Friday
Q4 2023 BIOLASE Inc Earnings Call
[BUY ALERT] Our #1 A.I. Stock for March
It's the one AI stock nobody is talking about. Cathy Wood just bought 11 million shares of it.
Recap: Biolase Q4 Earnings
Biolase: Q4 Earnings Snapshot
Earnings Preview For Biolase
BIOLASE (BIOL) Scheduled to Post Earnings on Thursday
Maxim Group Reaffirms Their Buy Rating on Biolase (BIOL)
See More Headlines
Receive BIOL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BIOLASE and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/10/2021
Today
3/28/2024
Next Earnings (Estimated)
5/09/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Dental equipment & supplies
Sub-Industry
N/A
Current Symbol
NASDAQ:BIOL
Previous Symbol
NASDAQ:BLTI
Employees
157
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$77.00
High Stock Price Target
$150.00
Low Stock Price Target
$4.00
Potential Upside/Downside
+40,193.0%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-20,630,000.00
Pretax Margin
-41.90%

Debt

Sales & Book Value

Annual Sales
$49.16 million
Book Value
($0.07) per share

Miscellaneous

Free Float
32,435,000
Market Cap
$6.21 million
Optionable
Not Optionable
Beta
0.62
13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

Key Executives


BIOL Stock Analysis - Frequently Asked Questions

Should I buy or sell BIOLASE stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BIOLASE in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" BIOL shares.
View BIOL analyst ratings
or view top-rated stocks.

What is BIOLASE's stock price target for 2024?

1 equities research analysts have issued 1-year price targets for BIOLASE's shares. Their BIOL share price targets range from $4.00 to $150.00. On average, they anticipate the company's stock price to reach $77.00 in the next year. This suggests a possible upside of 40,193.0% from the stock's current price.
View analysts price targets for BIOL
or view top-rated stocks among Wall Street analysts.

How have BIOL shares performed in 2024?

BIOLASE's stock was trading at $1.1220 on January 1st, 2024. Since then, BIOL shares have decreased by 83.0% and is now trading at $0.1911.
View the best growth stocks for 2024 here
.

Are investors shorting BIOLASE?

BIOLASE saw a increase in short interest during the month of March. As of March 15th, there was short interest totaling 288,900 shares, an increase of 17.6% from the February 29th total of 245,600 shares. Based on an average daily trading volume, of 4,800,000 shares, the days-to-cover ratio is presently 0.1 days. Approximately 0.9% of the shares of the company are short sold.
View BIOLASE's Short Interest
.

When is BIOLASE's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our BIOL earnings forecast
.

How were BIOLASE's earnings last quarter?

BIOLASE, Inc. (NASDAQ:BIOL) announced its quarterly earnings data on Wednesday, November, 10th. The medical technology company reported ($50.00) EPS for the quarter, topping the consensus estimate of ($75.00) by $25.00. The medical technology company earned $9.53 million during the quarter. BIOLASE had a negative net margin of 41.97% and a negative trailing twelve-month return on equity of 555.22%. During the same period last year, the business posted ($525.00) earnings per share.

When did BIOLASE's stock split?

BIOLASE shares reverse split before market open on Friday, July 28th 2023. The 1-100 reverse split was announced on Friday, July 28th 2023. The number of shares owned by shareholders was adjusted after the market closes on Friday, July 28th 2023. An investor that had 100 shares of stock prior to the reverse split would have 1 shares after the split.

What guidance has BIOLASE issued on next quarter's earnings?

BIOLASE issued an update on its first quarter 2024 earnings guidance on Thursday, March, 21st. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $10.0 million-, compared to the consensus revenue estimate of $10.8 million.

What is John R. Beaver's approval rating as BIOLASE's CEO?

4 employees have rated BIOLASE Chief Executive Officer John R. Beaver on Glassdoor.com. John R. Beaver has an approval rating of 13% among the company's employees. This puts John R. Beaver in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies. 35.0% of employees surveyed would recommend working at BIOLASE to a friend.

What other stocks do shareholders of BIOLASE own?
How do I buy shares of BIOLASE?

Shares of BIOL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:BIOL) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners